Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Cash (2020 - 2025)

Bioventus' Change in Cash history spans 6 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 708.18% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.7 million, up 109.09%, while the annual FY2025 figure was $9.7 million, 109.09% up from the prior year.
  • Change in Cash reached $9.1 million in Q4 2025 per BVS's latest filing, down from $9.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $42.6 million in Q2 2021 to a low of -$41.7 million in Q3 2022.
  • Average Change in Cash over 5 years is -$1.8 million, with a median of -$2.0 million recorded in 2022.
  • Peak YoY movement for Change in Cash: crashed 583.55% in 2022, then surged 708.18% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$31.7 million in 2021, then soared by 91.97% to -$2.5 million in 2022, then surged by 498.31% to $10.1 million in 2023, then tumbled by 114.72% to -$1.5 million in 2024, then soared by 708.18% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Change in Cash are $9.1 million (Q4 2025), $9.3 million (Q3 2025), and $10.1 million (Q2 2025).